Lv4
700 积分 2021-07-11 加入
Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2–3 trial
25天前
已完结
Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma
1个月前
已完结
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
2个月前
已完结
Integrating spatial gene expression and breast tumour morphology via deep learning
2个月前
已完结
Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer
3个月前
已完结
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration
4个月前
已完结
Definition of resectable stage III non-small cell lung cancer: A systematic review from EORTC lung cancer group
4个月前
已完结
Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer
4个月前
已完结
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
4个月前
已完结
Immune Checkpoint Inhibitor Outcomes for Patients With Non–Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications
6个月前
已完结
皖公网安备34019202002308
